-
Cancer Cell: A potential treatment for deadly childhood cancer
Time of Update: 2022-12-04
essayCancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma Image: Sheila Singh (left) and first author and postdoctoral researcher William GwynneSource: McMaster UniversityA study led by McMaster University says an enzyme that promotes the growth of deadly brain cancers in children could be key to future treatments.
-
Scientists discover potential "electrical language" for breast cancer cells
Time of Update: 2022-11-26
"We don't yet know why the voltage of cell membranes fluctuates in cancer cells, but our findings and technology, with exciting collaboration between engineers and biologists, opens the door to further work that could help us better understand cancer signaling networks and growth.
-
Neurology: Efficacy of endovascular thrombectomy in patients with acute stroke and cancer
Time of Update: 2022-11-26
A study published in Neurology used a large inpatient database, the National Inpatient Sample (NIS), to examine clinical outcomes in cancer patients undergoing EVT.
A study published in Neurology used a large inpatient database, the National Inpatient Sample (NIS), to examine clinical outcomes in cancer patients undergoing EVT.
-
Living ≠ life, so that patients can return to normal life, this is what we are pursuing
Time of Update: 2022-09-01
Anxiety at the time of diagnosis, collapse at the time of recurrence, standardization at the time of initial treatment, seriousness in maintenance, determination when returning to society, the mental
-
Application of alpha-fetoprotein detection in early screening of hepatocellular carcinoma (HCC
Time of Update: 2022-08-30
Enzyme-linked immunosorbent assay (ELISA) HCCHCCHCC References: 1) The clinical application of serum alpha-fetoprotein in assessing significant liver inflammation in patients with chronic hepatitis B -- Yang Kai, Guan Shihe, Zhang Hao, Wu Yuanyuan 2) The clinical application value of alpha-fetoprotein in detecting hepatocellular carcinoma -- Wu Hongsong, Wei Pengyu, Lee Tenghui, Yang Zhenyu, Du Xilin
-
Interpretation of the literature: metabolomics facilitates changes in intestinal and liver metabolites or new findings that can induce liver cancer
Time of Update: 2022-08-30
03 Experimental Results We performed an in-depth comprehensive metabolomic analysis of portal and central venous serum, liver tissue, and stool samples to identify HCC-related metabolites compared with healthy subjects .
-
"Philippine" long-term vision - case sharing: deep ketone reduction, full monitoring, triptorelin to help prostate cancer testosterone management
Time of Update: 2022-04-29
In order to improve the clinical diagnosis and treatment level of doctors related to urogenital tumors, Yimaitong invited Professor Li Jun from Sichuan Provincial People's Hospital to provide prostate cancer cases, and invited Professor Wang Shaogang from Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology to comment .
-
[Research News] The team of Professor Li Zifu and Professor Yang Xiangliang from the School of Life Sciences of Huazhong University of Science and Technology proposed a "precise and traceless" linker
Time of Update: 2022-03-03
Based on the above background, in this study, five different linker-conjugated doxorubicin (DOX) dimers were designed and synthesized: DOX2-CC linked with stable fatty chain, DOX2-SS (SH ), GSH-responsive and DOX2-SS with original drug release, H2O2-responsive and original drug-released DOX2-Bor, and acid-responsive and original drug-released DOX2-DMA, and were observed in mouse triple-negative breast cancer in situ tumors and Two different tumor-bearing mouse models of hepatocellular carcinoma were compared for their antitumor efficacy .
-
Express significantly prolongs the lives of Asian liver cancer patients, and Keytruda reaches the phase 3 primary clinical endpoint
Time of Update: 2021-10-11
(MSD) announced that in Asian patients with advanced hepatocellular carcinoma (HCC) who have received sorafenib (sorafenib), the heavyweight PD-1 antibody A phase 3 clinical trial of the therapy Keytruda reached the primary endpoint of overall survival (OS) .
-
AJG: The acid suppressant ranitidine may induce bladder cancer
Time of Update: 2021-09-10
Patients with bladder cancer cases and healthy controls (based on age, sex, date of registration) diagnosed between 1999 and 2011 were included in this study .
This study confirmed that the use of ranitidine, especially long-term use, is associated with an increased risk of bladder cancer .
-
PNAS: Staying up late will increase inhibitory neuron activity and destroy human memory
Time of Update: 2021-08-14
On August 5, 2021, researchers from the University of Michigan in the United States published a research paper titled Sleep loss drives acetylcholine- and somatostatin interneuron-mediated gating of hippocampal activity to inhibit memory consolidation in the Proceedings of the National Academy of Sciences (PNAS) .
-
Targeting Claudin 18.2 and 4-1BB
Time of Update: 2021-04-19
2, TJ-CD4B can still bind to tumor cells and produce better immune activity than other 4-1BB monoclonal antibodies, making it expected to be suitable for a wider range of patients group.
-
Millions of viruses have been injected into the brain, and the survival period of children with fatal tumors has more than doubled
Time of Update: 2021-04-18
Image source: 123RF In this trial, 12 patients with high-grade glioma aged 7-18 years received G207 treatment.
The research team also observed that the presence of HSV-1 antibodies in the body before treatment may affect the survival benefits of patients.
-
Nature Cancer: Studies have found that inhibiting EZH2 can activate the dsRNA–STING–interferon stress pathway that enhances the response to PD-1 checkpoint blockade in prostate tumors
Time of Update: 2021-03-26
American researchers Morel, KL, Sheahan, AV, Burkhart, DL and other studies have shown that EZH2 inhibition of prostate cancer model activates a double-stranded RNA-STANG-ISG stress response up-regulated gene, which is involved in antigen expression and Th1 chemokine signaling Reacts with interferon, including programmed cell death protein 1 (PD-L1), which is dependent on spinal activation.
-
Deqi Pharmaceuticals " first-in-class" anti-cancer drugs have been approved in China phase 3 clinical trials
Time of Update: 2021-01-04
On December 18, Deqi Pharmaceuticals announced that China's State Drug Administration (NMPA) had approved a Phase 3 clinical trial application for oral selective nuclear output inhibitors ATG-010 (selinexor) in a joint treatment of patients with recurring refractic multiple myeloma (MM) in China.
